|
Cullinan Oncology, Inc. (CGEM) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cullinan Oncology, Inc. (CGEM) Bundle
Entdecken Sie den wahren Wert von Cullinan Oncology, Inc. (CGEM) mit unserem fortschrittlichen DCF -Taschenrechner! Passen Sie wesentliche Annahmen an, erkunden Sie verschiedene Szenarien und bewerten Sie, wie sich unterschiedliche Faktoren auf die Bewertung der Cullinanonkologie auswirken - alles innerhalb einer einzigen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 18.9 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | -100 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -22.2 | -60.3 | -67.9 | 151.4 | -190.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | -358.45 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .1 | .1 | .1 | .1 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 0.27979 | 100 | 100 | 80.06 | 80.06 | 80.06 | 80.06 | 80.06 |
| EBIT | -22.3 | -60.3 | -68.0 | 151.3 | -190.6 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | -358.73 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 98.6 | 210.2 | 430.9 | 550.1 | 467.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | .9 | 9.7 | 3.2 | 2.7 | 2.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 16.73 | 100 | 100 | 83.35 | 83.35 | 83.35 | 83.35 | 83.35 |
| Capital Expenditure | .0 | .0 | -.6 | -1.1 | -.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | -3.11 | 100 | 100 | -0.6221 | -0.6221 | -0.6221 | -0.6221 | -0.6221 |
| Tax Rate, % | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 |
| EBITAT | -20.6 | -51.6 | -65.5 | 111.2 | -172.6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.6 | -42.8 | -72.5 | 109.7 | -172.6 | -2.5 | .0 | .0 | .0 | .0 |
| WACC, % | 5.3 | 5.3 | 5.3 | 5.29 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 | 5.3 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -95 | |||||||||
| Equity Value | 92 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | 2.23 |
What You Will Receive
- Pre-Loaded Financial Model: Cullinan Oncology's actual data provides accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Gain access to reliable pre-loaded historical figures and future forecasts for Cullinan Oncology, Inc. (CGEM).
- Adjustable Forecast Parameters: Modify yellow-highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries that make it easy to interpret your valuation outcomes.
- Designed for All Users: A straightforward, user-friendly layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based CGEM DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Cullinan Oncology’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Cullinan Oncology, Inc. (CGEM)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for CGEM.
- Customizable Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
- Detailed Insights: Automatically computes Cullinan Oncology’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide a solid foundation for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on CGEM.
Who Should Use This Product?
- Investors: Accurately assess Cullinan Oncology’s fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to CGEM.
- Consultants: Efficiently modify the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Implement it as a teaching resource to illustrate valuation techniques in the healthcare industry.
What the Template Contains
- Historical Data: Includes Cullinan Oncology’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Cullinan Oncology’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Cullinan Oncology’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.